These drugs reduce production of the abnormal transthyretin protein in the liver, which is responsible for many cases of ...

Patients are now being identified earlier than ever, and new drugs approved by the FDA are prolonging their lives significantly.

Cardiac amyloidosis is a progressive condition that affects the heart and other organs, but new FDA-approved drugs are prolonging the lives of those affected and early identification is now possible.

Chicago, Illinois (Embargoed until 1:33 p.m. CDT, Sunday, June 25, 2023)—Researchers have identified the optimal tracer kinetic model to quantify 18F-flutemetamol myocardial uptake in patients with ...

Please provide your email address to receive an email when new articles are posted on . An AI model accurately distinguished cardiac amyloidosis from other phenotypic mimics. The model also showed ...

Although it is rare, cardiac amyloidosis is an important heart disease to pay attention to because its symptoms can be easy to overlook and often resemble those of other heart ...

This news comes amid a push within value-based care to ensure high-cost medical interventions deliver meaningful improvements ...

This transcript has been edited for clarity. Gayatri Acharya, MD: Greetings. I'm Dr Gayatri Acharya, cardiology fellow at Mayo Clinic. During today's roundtable, we'll be discussing cardiac ...

Please provide your email address to receive an email when new articles are posted on . Cardiac MRI data suggest acoramidis could improve outcomes for people with symptomatic transthyretin amyloid ...

AT-02, the company’s lead pan-amyloid removal therapeutic candidate, is currently being evaluated in a Phase 1 three-part trial and a Phase 2 open label extension trial in ATTR and AL amyloidosis ...